Efficacy
The median follow up period was 47 months. At 60 months, 59% (95% CI, 53 to 65) of patients in the chemoradiation group were alive and relapse-free vs 58% (95% CI, 53 to 64) in the chemotherapy only group (HR 0.90; 90% CI, 0.74 to 1.10).r
Chemoradiation was associated with a lower 5 year incidence of vaginal recurrence (2% vs 7%; HR 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph node recurrence (11% vs 20%; HR 0.43; 95% CI, 0.28 to 0.66) compared with chemotherapy only. However distant recurrence was more common in the chemoradiation vs chemotherapy only group (27% vs 21%; HR 1.36; 95% CI, 1.00 to 1.86).
Kaplan-Meier curves for relapse-free survivalr
© N Engl J Med 2019
Overall survival data are not yet mature.
There was no clinically meaningful difference in the quality of life scores between the two groups.